Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
2026-03-09 14:38:32 ET
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK) , exercised 15,000 options for common stock and immediately sold the resulting shares in an open-market transaction totaling approximately $928,950, according to the SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average purchase price ($61.93); post-transaction value based on Feb. 5, 2026 market close ($60.24).
Cytokinetics is a late-stage biopharmaceutical company specializing in muscle biology, with a strategic focus on novel therapeutics for debilitating cardiac and neuromuscular conditions. The company leverages advanced small molecule research and clinical development capabilities to build a pipeline of differentiated assets. Its competitive position is supported by a robust clinical portfolio and strategic alliances within the healthcare industry.
NASDAQ: CYTK
CYTK Trading
3.56% G/L:
$63.905 Last:
620,280 Volume:
$62.24 Open:
